Repotrectinib (Augtyro) – targeted treatment review for ROS1 and NTRK tumors

What repotrectinib is in simple patient language

Repotrectinib is the drug name. Augtyro is the brand name. A cancer capsule. Not classic chemotherapy. Not immunotherapy. Not a capsule to start because a report says one familiar word.

This drug comes into the discussion when the tumor file shows a real ROS1 or NTRK change. The name of the gene matters, but it is not the whole answer. The old treatment story matters too.

For the family, the first talk is practical. What was found in the tumor? Where is the disease now? What has already been tried? Any brain spots? Any dizziness, falls, liver trouble, breathing change, or strong weakness at home? Those details can change the plan.

How repotrectinib works

Some tumors keep moving because one inner signal stays on. In this group, the signal may be linked to ROS1 or NTRK. Repotrectinib tries to quiet that route.

When the tumor is still using that signal, the drug may slow the disease. Sometimes scans improve. Sometimes the useful result is quieter: the disease stops racing for a while.

The same capsule can also cause trouble outside the tumor. Balance, sleepiness, numbness, breathing, liver tests, muscle pain, and daily strength all need attention. So the review is never only about the gene name.

Which diseases or situations repotrectinib may be used for

Repotrectinib is not a drug for every cancer diagnosis. It belongs only in cases where the test result gives the doctor a clear reason to discuss this route.

• lung cancer with a confirmed ROS1 change
• disease that has spread and needs body-wide treatment
• a new step after an older ROS1 drug no longer gives enough control
• solid tumors with an NTRK change, when this route fits the case
• situations where brain scans, balance, or nerve symptoms are part of the story
• a second opinion when Augtyro was offered and the reason is not clear

The same lab word can mean different things in different people. A fresh scan, a new symptom, or a past side effect can move the decision in another direction.

When repotrectinib can be especially relevant

This drug is usually discussed when the file points to a molecular route, not when the doctor is simply looking for another standard option.

• the ROS1 result is clear and the disease needs systemic treatment
• an earlier ROS1 medicine helped for a time and then stopped doing enough
• new scans suggest that the tumor has changed its behavior
• an NTRK result is present and other routes look limited
• brain MRI, dizziness, falls, or nerve symptoms need to be part of the review
• the patient wants another opinion before starting the next line

The useful question is not only whether the drug is new. It is what this drug is meant to do now: slow growth, help symptoms, control brain-related risk, or buy time with a safer plan.

What needs to be checked before treatment

Before Augtyro starts, the doctor needs the real file, not only one line from a report.

• the exact tumor type and biopsy result
• the ROS1 or NTRK test, with the method and date
• which tissue or blood sample was used for the test
• recent CT, PET-CT, MRI, or brain MRI when needed
• all earlier cancer medicines, dates, response, and reason for stopping
• blood count, liver values, kidney values, and other recent labs
• dizziness, falls, numbness, sleepiness, memory change, or trouble walking
• cough, new breathing trouble, chest pain, or fever
• heart history, ECG if relevant, and the full daily medicine list

A small note can become the main issue. A fall last week. A liver test that is rising. A medicine that does not mix well. A patient already too sleepy or weak. These are not side details.

How treatment with repotrectinib goes

Repotrectinib is taken by mouth on the schedule given by the oncologist. No guessed dose changes. No old capsules restarted after a break. No skipped plan without telling the team.

The patient may be at home, but the care is still cancer care. The first weeks are about both the tumor and the person carrying the treatment.

During treatment, the doctor usually follows:

• balance: how the patient walks, turns, and gets up from a chair
• new numb patches, tingling, or pins-and-needles in the hands or feet
• blood work, including liver and kidney numbers, when the schedule calls for it
• new breath changes, a rough cough, chest tightness, or fever
• muscle aches, heavy weakness, swelling, appetite, and weight changes
• scan timing and whether the cancer is changing

One rough week does not automatically close this route. The next move may be a brief stop, a smaller dose, extra blood work, fluids, or another small support step. The decision belongs with the treating doctor.

Possible side effects

Repotrectinib can help some patients, but the body can still pay part of the price. Some people mainly notice dizziness or sleepiness. For others, the first clue is tingling, an unsettled stomach, swelling, or a lab number that no longer looks usual.

• dizzy spells, unsteady steps, a fall, or trouble keeping balance
• sleepiness, slower thinking, confusion, or memory change
• pins-and-needles, burning, numb patches, or odd sensations in the arms or legs
• changed taste, nausea, constipation, smaller meals, or weight change
• new cough, breathing that feels different, or pressure in the chest
• muscle or joint aches, heavy tiredness, swelling, or weight moving up
• liver numbers, uric acid, or another lab result moving out of range

Not every symptom means danger. The danger is silence. A small fall, new breathlessness, or a strange sleepy feeling is easier to sort out early.

When the treating team needs to know fast

Call or message the treating team the same day if any of this starts:

• a fall, strong dizziness, or walking that suddenly feels unsafe
• confusion, unusual sleepiness, or behavior that is not normal for the patient
• new breathing trouble, chest pain, fever with cough, or fast worsening
• dark urine with strong muscle pain or sudden heavy weakness
• fainting, strong heartbeat changes, or pressure in the chest
• yellow eyes or skin, very dark urine, or severe belly pain
• swelling that comes quickly, rapid weight change, or any sharp decline

Do not try to prove at home that Augtyro is the cause. The patient needs help before the situation becomes bigger.

Why repotrectinib is not right for everyone

Repotrectinib can be a strong option in the right file. It is not a general answer for all lung cancers or all tumors with genetic testing.

• ROS1 or NTRK was not truly confirmed
• the old test is too old for the current question
• the patient already has severe dizziness, falls, or nerve symptoms
• liver tests, lung symptoms, or daily strength make the start unsafe
• the medicine list creates a serious interaction problem
• another treatment, local procedure, or study is the better next step

When the doctor says no or not now, it does not mean the drug is bad. It may mean the timing, the risk, or the tumor story points elsewhere.

Can repotrectinib be combined with other treatments

Sometimes Augtyro sits inside a wider plan. It is not added just to make a plan look stronger. Each step needs a reason.

• after an earlier targeted drug
• after radiation or another local treatment for one problem spot
• with support for nausea, pain, swelling, or lab changes
• while comparing the next line with chemotherapy or a clinical study
• after a fresh review of the medicine list and interaction risks

The order matters. What was tried first. What failed. What helped. What is urgent now. A safe plan often depends on that order more than on the drug name alone.

What no quick response can mean

No quick change does not always mean failure. With targeted treatment, the first clear answer often comes from planned scans, not from the first few days of feeling better or worse.

Sometimes the good news is obvious shrinkage. Sometimes it is quieter disease, fewer symptoms, or a slower pace. In advanced cancer, that can still matter.

The doctor looks at scans, labs, symptoms, balance, breathing, side effects, and the speed of the disease before treatment. One sign alone rarely tells the whole story.

Oncology consultation in Israel about repotrectinib

At Tel Aviv Medical Clinic, patients can discuss whether repotrectinib has a place in their case: a lung tumor with a ROS1 finding, a solid tumor with an NTRK finding, growth after another targeted drug, or a plan that is still unclear to the family.

A consultation can help with:

• checking the ROS1 or NTRK report
• understanding why Augtyro was offered
• reviewing older targeted drugs and why they stopped
• looking at brain MRI, dizziness, falls, and nerve symptoms in the plan
• checking liver, lung, heart, and medicine-list risks
• preparing questions for the treating oncologist
• discussing consultation or treatment in Israel

We do not prescribe treatment remotely and do not replace the treating doctor. The goal is to help the patient and family understand the medical logic before the next step.

Frequently asked questions – answered by Dr. Stefanska

1. Is repotrectinib chemotherapy?

No. It is a targeted capsule. It is used only when the tumor has a real ROS1 or NTRK reason for this type of treatment.

Still, it is not a light home pill. I want a plan for blood tests, scans, balance, breathing, liver values, and the medicines the patient already takes.

2. Why is the ROS1 or NTRK test so important?

Because without that result, the drug has no clear target. The cancer name is not enough.

I want to see the actual report: what was found, when the test was done, and what sample was used. If many treatments happened after that test, the file may need a fresh look.

3. Can Augtyro be used after another ROS1 drug?

Sometimes yes. But first I need the old story. Which drug? How long did it help? Why did it stop? What do the newest scans show?

A new capsule is useful only if it fits the way the disease is behaving now. Otherwise, the next step may be a different drug, a local treatment, chemotherapy, or a study.

4. Why does the doctor ask about dizziness and falls?

Because this drug can affect balance and the nervous system. Dizziness, sleepiness, numbness, slow thinking, or falls are not small details here.

Tell the doctor early. A dose hold, extra tests, or a safer home plan may prevent a bigger problem.

5. What if breathing gets worse or a new cough starts?

Do not sit with it for days. Call the team, especially with fever, chest pain, or a new change in breathing.

It could be an infection. It could be the cancer, the lung, or a treatment reaction. The safe answer comes from checking, not guessing.

6. When do we know if the treatment is helping?

Usually not after one day. The doctor needs the scans, the blood work, and the symptom story from more than one day.

Sometimes the mass gets smaller. Sometimes the better sign is quieter: the cancer stops running ahead. I look at the trend, not one number by itself.

7. What should be sent for a second opinion about Augtyro?

Send the biopsy report, the ROS1 or NTRK result, recent scans, brain MRI if it was done, blood work, liver results, and the treatment list in order.

Add the short story: what was tried, what worked, why it stopped, and which side effects were hardest. That helps more than a pile of unsorted pages.

Important information

This page gives general medical information. It is not a treatment prescription. Repotrectinib can be discussed only after the diagnosis, molecular report, scans, previous treatment, current symptoms, labs, and general condition are reviewed by the treating doctor.

Do not start, stop, pause, restart, or change the dose without the treating doctor.

Contacts

For a consultation about repotrectinib:

📞 +972-73-374-6844

📧 [email protected]

💬 WhatsApp: +972-52-337-3108